Clinical Trial

Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.

Study acronym: CONVERSION
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy. There is a growing need for more effective treatment in patients with liver-only mCRC to improve the rate of curative resection without compromising QOL.The current study is informed by our patient's needs. It aims to evaluate the rate of conversion therapy in patients with unresectable liver-only mCRC using the combination of FOLFOXIRI and bevacizumab and to assess the association between an early FDG-PT/CT response and other clinical and pathological biomarkers and hepatic metastasectomy.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2018-01-16; most recent amendment 2025-05-07.
Status change: Not Yet Recruiting → Recruiting 2025-05-07
Trial Details
NCT Number NCT03401294
Lead Sponsor University of Saskatchewan
Conditions Metastatic Colorectal Cancer
Enrollment 32 participants
Start Date 2025-05-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-09